South Korean customs officials say they are intercepting a rising number of illegally imported weight-loss and diabetes medicines, as travelers take advantage of markedly lower prices in Japan.
At the center of the trend is Mounjaro, a prescription drug used to treat type 2 diabetes that has also become popular for weight loss. According to reports from Seoul, more South Koreans visiting Japan are purchasing the medicine there and attempting to bring it back without proper authorization, encouraged by the significant gap in retail cost between the two countries.
The price difference is stark: South Korean visitors can reportedly buy Mounjaro in Japan for roughly one-third of what they would pay at home. That disparity appears to be fueling a steady increase in attempts to carry supplies back into South Korea outside official import channels—an activity that can violate customs rules and pharmaceutical regulations.
Authorities say seizures of these medications at the border have surged this year, reflecting both the growing demand for the drug and the expanding incentives created by diverging prices. While the specific volume of confiscations was not detailed, customs officials characterized the increase as sharp compared with previous periods.
The enforcement actions highlight the tension many countries now face as newer metabolic drugs become sought after well beyond their original purpose. Medicines like Mounjaro are tightly regulated because they require medical oversight, can carry side effects, and must be properly stored and transported to remain safe and effective. Officials also warn that informal import routes make it harder to verify authenticity and trace supply chains—factors that can raise the risk of counterfeit or mishandled products entering the market.
For South Korea, the spike in seizures underscores how cross-border travel can quickly become a conduit for unauthorized pharmaceutical trade when demand is high and price differentials are large. It also reflects the broader wave of interest in injectable diabetes medications being used for weight management, which has put pressure on supply and regulatory systems in multiple countries.
Customs authorities have not only stepped up inspections but are also using seizure data as a signal of changing consumer behavior. The pattern suggests that, for some travelers, the perceived savings outweigh the legal and health risks of bypassing formal channels.
Why it matters
The crackdown affects travelers, patients, and regulators as demand for Mounjaro grows for both diabetes care and weight loss. Rising seizures point to a widening price gap and potential strain on legitimate access, as well as increased risks from unverified products. What happens next will depend on enforcement intensity, pricing dynamics, and whether authorities adjust policies to curb illicit imports while maintaining safe access for patients.